Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is expected to release its Q4 2024 earnings data before the market opens on Monday, March 31st. Analysts expect Cardiol Therapeutics to post earnings of ($0.08) per share for the quarter.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cardiol Therapeutics Stock Performance
Cardiol Therapeutics stock traded down $0.01 during mid-day trading on Thursday, reaching $0.91. 205,795 shares of the company were exchanged, compared to its average volume of 385,320. The firm's 50-day simple moving average is $1.19 and its two-hundred day simple moving average is $1.50. Cardiol Therapeutics has a twelve month low of $0.86 and a twelve month high of $3.12. The firm has a market cap of $75.17 million, a PE ratio of -2.33 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on CRDL. Rodman & Renshaw began coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $7.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday, February 24th. Finally, RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 28th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $8.40.
View Our Latest Stock Report on CRDL
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
